Current Illinois CancerCare Clinical Trals

Non-Hodgkin's Lymphoma


GO44145

A Phase III, Multicenter, Randomized, Open‑Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (POLA-R-CHP) Versus POLA‑R‑CHP in Previously Untreated Patients with Large B-Cell Lymphoma


M22-003

Study of Subcutaneous Epcoritamab in Combination with Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants with Previously Untreated Follicular Lymphoma (EPCORE™FL-2)


Search Again